title: Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients.
abstract: OBJECTIVE
  Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon (IFN)-beta. Early identification of nonresponder patients is crucial to try different therapeutic approaches. We investigated various criteria of treatment response to assess which criterion better identifies patients with a poor response.
  
  
  METHODS
  We studied relapsing-remitting MS (RRMS) patients treated with IFN-beta and followed them up for at least 2 years. Expanded Disability Status Score was scored every 3 months and relapses were recorded. We analyzed various criteria based on relapses, disability progression, or both.
  
  
  RESULTS
  Three hundred ninety-three patients were included. After 2 years of treatment, we observed a proportion of nonresponders, ranging from 7 to 49% depending on the stringency of the criteria used. Criteria based in disability progression had higher sensitivity, specificity, and accuracy. The hazard ratio for the development of marked disability after 6 years of treatment was 39.6 (95% confidence interval, 16.6-94.4) among the patients who fulfilled the criterion based only in disability progression.
  
  
  CONCLUSIONS
  Criteria of response to IFN-beta therapy in RRMS using disability progression are more clinically relevant than those based only in relapse rate. This finding may be important for the counseling and care of RRMS patients treated with IFN-beta.
authors.affiliation: 2TM planta EUI, Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron, Barcelona, Spain. jrio@vhebron.net
authors.forename: Jordi
authors.initials: J
authors.lastname: Río
authors.forename: Carlos
authors.initials: C
authors.lastname: Nos
authors.forename: Mar
authors.initials: M
authors.lastname: Tintoré
authors.forename: Nieves
authors.initials: N
authors.lastname: Téllez
authors.forename: Ingrid
authors.initials: I
authors.lastname: Galán
authors.forename: Raúl
authors.initials: R
authors.lastname: Pelayo
authors.forename: Manuel
authors.initials: M
authors.lastname: Comabella
authors.forename: Xavier
authors.initials: X
authors.lastname: Montalban
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D003710:Demography; D004185:Disability Evaluation; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D008297:Male; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta